Free Trial
→ Trump’s Plan To Cheat History (From Porter & Company) (Ad)tc pixel
NASDAQ:PVLA

Palvella Therapeutics Q3 2026 Earnings Date & Estimates

Palvella Therapeutics logo
$146.15 -5.43 (-3.58%)
Closing price 10/30/2026 04:00 PM Eastern
Extended Trading
$148.99 +2.84 (+1.94%)
As of 10/30/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palvella Therapeutics is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 8:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
8:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Palvella Therapeutics in Q3 2026

Palvella Therapeutics is expected to post earnings of -$1.78 per share on revenue of $17 thousand. In the same quarter a year earlier Palvella Therapeutics reported -$1.03 per share. Palvella Therapeutics last reported on August 4, 2026, posting -$1.52 per share and missing the -$1.17 consensus estimate. Palvella Therapeutics has beaten the consensus EPS estimate in 1 of its last 6 quarters.

Consensus Estimates

Consensus EPS
-$1.78
Expected Revenue
$17 thousand
Prior-Year EPS
-$1.03

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$1.52 (Missed by -$0.35)
EPS Beat Rate
1 of last 6 quarters

Prepare for the Q3 2026 Call

Palvella Therapeutics Q3 2026 Earnings FAQ

Palvella Therapeutics (NASDAQ:PVLA) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Palvella Therapeutics' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 8:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Palvella Therapeutics to post earnings of -$1.78 per share for Q3 2026.

The consensus revenue estimate for Palvella Therapeutics is $17 thousand for Q3 2026.

Palvella Therapeutics Earnings Headlines

Palvella Therapeutics (NASDAQ:PVLA) Earns Buy Rating from Chardan Capital
October 30 at 2:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31166979
Palvella Therapeutics to Host Third Quarter 2026 Financial Results and Corporate Update Conference Call on November 5, 2026
October 29 at 8:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/29/3391161/0/en/palvella-therapeutics-to-host-third-quarter-2026-financial-results-and-corporate-update-conference-call-on-november-5-2026.html
The government is buying stocks
Donald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.tc pixel
 |  Porter & Company (Ad)
Palvella Gets FDA Priority Review For QTORIN Rapamycin; Decision Expected In February 2027; Stock Up
October 28, 2026  |  rttnews.comhttps://www.rttnews.com/3704441/palvella-gets-fda-priority-review-for-qtorin-rapamycin-decision-expected-in-february-2027-stock-up.aspx
Palvella Announces FDA Acceptance and Priority Review of QTORIN™ Rapamycin NDA; February 28, 2027 PDUFA Target Action Date Set
October 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/28/3390054/0/en/palvella-announces-fda-acceptance-and-priority-review-of-qtorin-rapamycin-nda-february-28-2027-pdufa-target-action-date-set.html
Palvella Therapeutics (NASDAQ:PVLA) Shares Cross Above Two Hundred Day Moving Average Following Insider Selling
October 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31162466
See More Palvella Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Palvella Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Palvella Therapeutics and other key companies, straight to your email.

About Palvella Therapeutics

Palvella Therapeutics (NASDAQ:PVLA) (NASDAQ: PVLA) is a clinical-stage biopharmaceutical company focused on developing treatments for patients with serious rare diseases, including conditions that may have limited or no approved therapeutic options.

The company’s development programs are based on its QTORIN 3.0 technology platform, which is designed to deliver medicines locally through topical formulations. Palvella has applied the platform to investigational therapies for rare genetic skin disorders and other localized diseases, with the goal of improving treatment effectiveness while limiting systemic exposure.

Palvella is headquartered in Wayne, Pennsylvania, and conducts research and development activities aimed at serving rare-disease patients in the United States and other potential international markets. Its product candidates remain subject to clinical testing and regulatory review before they can be marketed broadly.

View Palvella Therapeutics Profile
Earnings Tools